After signing up, you'll start to receive regular news updates from us.
Affymetrix Selected to Genotype 9,000 Framingham Heart Study Samples
Complete the form below to unlock access to ALL audio articles.
Affymetrix Inc. has announced that it has been selected by the SHARE (SNP Health Association REsource) project for a large-scale whole-genome association study.
As part of the project, Affymetrix will collaborate with the National Heart, Lung, and Blood Institute (NHLBI) and the National Center for Biotechnology Information (NCBI) of the National Institutes of Health to identify genetic variants associated with heart, lung, blood and sleep disorders.
The SHARE project will analyze 9,000 samples collected by the NHLBI and Boston University for the Framingham Heart Study.
Clinicians have been using the Framingham Heart Study to track and measure data relating to cardiovascular disease since 1948.
Data has been collected from 15,000 samples spanning three generations of individuals.
"The Framingham Heart Study is one of the most recognized clinical research projects in history and we are honored that the NHLBI has entrusted the genotyping of these valuable samples to Affymetrix," said Giulia C. Kennedy, Ph.D., senior director of genomics collaborations at Affymetrix.
"Researchers have been waiting for decades for the right technology to come along and extract the genetic information contained in these samples."
"When this project is complete, researchers around the globe will have access to one of the richest medical datasets in existence."
The Affymetrix 500K Array is designed to offer a comprehensive view of the genome, enabling researchers to analyze 500,000 markers simultaneously and perform whole-genome analyses in large populations.
As part of the SHARE project, researchers will develop a data resource that will integrate genome-wide genotypic information with phenotypic information from multiple NHLBI studies.
The data will be available to the scientific community for further genome-wide association analyses and will complement the data included in the recently announced Affymetrix Control Program.
"The SHARE project is extremely important and Affymetrix is excited to offer the genotyping technology and services," said Gregory Marcus, Ph.D., senior product manager at Affymetrix.
"Our technology is making these large-scale studies possible and affordable today."
"After this project is completed, researchers will be able to run complementary data sets that can be used in conjunction with the data from the Framingham Heart Study."
